Effettuare il login Iscriviti gratis

180 Life Sciences Avanti P/E

Cos'è Avanti P/E di 180 Life Sciences?

Avanti P/E di 180 Life Sciences Corp. è 6.08

Qual è la definizione di Avanti P/E?



Il rapporto prezzo / utili a termine è il rapporto tra il prezzo delle azioni di una società e l'utile stimato per azione della società per i prossimi dodici mesi.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Avanti P/E di aziende nel Health Care settore su NASDAQ rispetto a 180 Life Sciences

Cosa fa 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Aziende con avanti p/e simili a 180 Life Sciences